Brief: Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate

Sangamo Therapeutics

24/07/2024 11:45

July 24 (Reuters) - Pfizer Inc  PFE.N :
    * PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3
STUDY OF
HEMOPHILIA A GENE THERAPY CANDIDATE
    * PFIZER: ANALYSES OF FULL PHASE 3 DATASET FROM AFFINE STUDY
ONGOING
    * PFIZER: IN AFFINE STUDY, GIROCTOCOGENE FITELPARVOVEC WAS
GENERALLY WELL TOLERATED
    * PFIZER: AFFINE STUDY MEETS PRIMARY AND KEY SECONDARY
OBJECTIVES

Source text for Eikon:  ID: 
Further company coverage:  PFE.N 

 ((Reuters.Briefs@thomsonreuters.com;))